Abstract
Currently available antipsychotic drugs target dopaminergic neurotransmission. Many patients do not respond fully to these treatments, and there has been considerable effort to investigate alternative targets. Here we summarise the rationale and recent evidence supporting efforts to develop glutamatergic antipsychotic drugs. © The British Journal of Psychiatry 2013.
Cite
CITATION STYLE
APA
Papanastasiou, E., Stone, J. M., & Shergill, S. (2013). When the drugs don’t work: The potential of glutamatergic antipsychotics in schizophrenia. British Journal of Psychiatry, 202(2), 91–93. https://doi.org/10.1192/bjp.bp.112.110999
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free